Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers Squibb (NYSE: BMY) has announced its participation in two major investor conferences in November 2024. At Guggenheim's Inaugural Healthcare Innovation Conference on November 11, Dr. Samit Hirawat (EVP, Chief Medical Officer) and Dr. Robert Plenge (EVP, Chief Research Officer) will participate in a fireside chat at 10:00 a.m. ET. Later, at the 2024 Jefferies London Healthcare Conference on November 19, David Elkins (EVP, CFO) will join a fireside chat at 9:30 a.m. GMT. Both sessions will be accessible to investors and the public through the company's investor website, with archived recordings available afterward.
Bristol Myers Squibb (NYSE: BMY) ha annunciato la sua partecipazione a due importanti conferenze per investitori a novembre 2024. Durante il Guggenheim's Inaugural Healthcare Innovation Conference l'11 novembre, il Dr. Samit Hirawat (EVP, Chief Medical Officer) e il Dr. Robert Plenge (EVP, Chief Research Officer) parteciperanno a una conversazione informale alle 10:00 ET. Successivamente, il 2024 Jefferies London Healthcare Conference il 19 novembre, David Elkins (EVP, CFO) parteciperà a una conversazione informale alle 9:30 GMT. Entrambe le sessioni saranno accessibili agli investitori e al pubblico attraverso il sito web degli investitori dell'azienda, con registrazioni archiviate disponibili successivamente.
Bristol Myers Squibb (NYSE: BMY) ha anunciado su participación en dos importantes conferencias para inversores en noviembre de 2024. En la Guggenheim's Inaugural Healthcare Innovation Conference el 11 de noviembre, el Dr. Samit Hirawat (EVP, Chief Medical Officer) y el Dr. Robert Plenge (EVP, Chief Research Officer) participarán en una charla informal a las 10:00 a.m. ET. Más tarde, en la 2024 Jefferies London Healthcare Conference el 19 de noviembre, David Elkins (EVP, CFO) se unirá a una charla informal a las 9:30 a.m. GMT. Ambas sesiones estarán disponibles para inversores y el público a través del sitio web para inversores de la compañía, con grabaciones archivadas disponibles después.
Bristol Myers Squibb (NYSE: BMY)는 2024년 11월에 개최되는 두 개의 주요 투자자 회의에 참가할 것이라고 발표했습니다. Guggenheim's Inaugural Healthcare Innovation Conference가 11월 11일에 열리며, Samit Hirawat 박사 (EVP, Chief Medical Officer)와 Robert Plenge 박사 (EVP, Chief Research Officer)가 오전 10:00 ET에 진행되는 대화에 참여합니다. 이어서 2024 Jefferies London Healthcare Conference가 11월 19일에 열리며, David Elkins (EVP, CFO)가 오전 9:30 GMT에 대화에 참가합니다. 두 세션 모두 투자자와 대중이 회사의 투자자 웹사이트를 통해 접근할 수 있으며, 이후에 아카이브된 녹화본이 제공될 예정입니다.
Bristol Myers Squibb (NYSE: BMY) a annoncé sa participation à deux grandes conférences pour investisseurs en novembre 2024. Lors de la Guggenheim's Inaugural Healthcare Innovation Conference le 11 novembre, le Dr Samit Hirawat (EVP, Chief Medical Officer) et le Dr Robert Plenge (EVP, Chief Research Officer) participeront à une discussion informelle à 10h00 ET. Plus tard, à la 2024 Jefferies London Healthcare Conference le 19 novembre, David Elkins (EVP, CFO) rejoindra une discussion informelle à 9h30 GMT. Les deux sessions seront accessibles aux investisseurs et au public via le site des investisseurs de l'entreprise, avec des enregistrements archivés qui seront disponibles par la suite.
Bristol Myers Squibb (NYSE: BMY) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im November 2024 bekannt gegeben. Am Guggenheim's Inaugural Healthcare Innovation Conference am 11. November werden Dr. Samit Hirawat (EVP, Chief Medical Officer) und Dr. Robert Plenge (EVP, Chief Research Officer) um 10:00 Uhr ET an einem informellen Gespräch teilnehmen. Später, am 2024 Jefferies London Healthcare Conference am 19. November, wird David Elkins (EVP, CFO) um 9:30 Uhr GMT an einem informellen Gespräch teilnehmen. Beide Sitzungen werden für Investoren und die Öffentlichkeit über die Investorenseite des Unternehmens zugänglich sein, mit später verfügbaren Archivaufnahmen.
- None.
- None.
Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer and Head of Development, and Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer, will take part in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference. They will answer questions about the company beginning at 10:00 a.m. ET on November 11, 2024.
David Elkins, Executive Vice President, Chief Financial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on November 19, 2024. He will answer questions about the company beginning at 9:30 a.m. GMT (
Investors and the general public are invited to listen to both sessions at their respective times by visiting http://investor.bms.com. An archived edition of each session will be available following its conclusion.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook, and Instagram.
corporatefinancial-news
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105721845/en/
Media:
media@bms.com
Investors:
investor.relations@bms.com
Source: Bristol Myers Squibb
FAQ
When will Bristol Myers Squibb (BMY) present at Guggenheim's Healthcare Innovation Conference in 2024?
Who will represent BMY at the 2024 Jefferies London Healthcare Conference?
How can investors access BMY's presentations at the November 2024 conferences?
What time is BMY's presentation at the 2024 Jefferies London Healthcare Conference?
